TY  - JOUR
AU  - Rosager, A.M.
AU  - Sorensen, M.D.
AU  - Dahlrot, R.H.
AU  - Boldt, H.B.
AU  - Hansen, S.
AU  - Lathia, J.D.
AU  - Kristensen, B.W.
PY  - 2017//
TI  - Expression and prognostic value of JAM-A in gliomas
T2  - J Neurooncol
JO  - Journal of Neuro-Oncology
KW  - Astrocytic brain tumors
KW  - Glioma
KW  - Junctional adhesion molecule-A
KW  - Prognosis
KW  - Tumor stem cell
AB  - Gliomas are among the most lethal cancers, being highly resistant to both chemo- and radiotherapy. The expression of junctional adhesion molecule-A (JAM-A) was recently identified on the surface of stem cell-like brain tumor-initiating cells and suggested to function as a unique glioblastoma niche adhesion factor influencing the tumorigenic potential of brain tumor-initiating cells. We have recently identified high JAM-A expression to be associated with poor outcome in glioblastomas, and our aim was to further investigate the expression of JAM-A in gliomas focusing especially on the prognostic value in WHO grade II and III gliomas. JAM-A protein expression was evaluated by immunohistochemistry and advanced quantitative image analysis with continuous estimates of staining intensity. The JAM-A antibody stained tumor cell membranes and cytoplasm to various extent in different glioma subtypes, and the intensity was higher in glioblastomas than low-grade gliomas. We could not detect an association with overall survival in patients with grade II and III tumors. Double-immunofluorescence stainings in glioblastomas revealed co-expression of JAM-A with CD133, SOX2, nestin, and GFAP in tumor cells as well as some co-expression with the microglial/macrophage marker IBA-1. In conclusion, JAM-A expression was higher in glioblastomas compared to low-grade gliomas and co-localized with recognized stem cell markers suggesting an association of JAM-A with glioma aggressiveness. No significant association between JAM-A expression and overall survival was found in grade II and III gliomas. Further research is needed to determine the function and clinical impact of JAM-A in gliomas.
SN  - 0167-594X
UR  - http://www.ncbi.nlm.nih.gov/pubmed/28677106
UR  - PM:28677106
N1  - PMID:28677106
ID  - Rosager_etal2017
ER  -